Addressing Involuntary Movements in Tardive Dyskinesia
Status:
Completed
Trial end date:
2016-08-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether fixed-doses of an investigational drug,
SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of
tardive dyskinesia.